Stockwatch: Will Biogen Keep Digging After Tough Quarter?
Weak Financials May Not Be The Last Shoe To Drop
Executive Summary
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.